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The yeast mating response is one of the best understood hetero-
trimeric G protein signaling pathways. Yet, most descriptions of
this system have been qualitative. We have quantitatively charac-
terized the heterotrimeric G protein cycle in yeast based on direct
in vivo measurements. We used fluorescence resonance energy
transfer to monitor the association state of cyan fluorescent
protein (CFP)-G and G-yellow fluorescent protein (YFP), and we
found that receptor-mediated G protein activation produced a loss
of fluorescence resonance energy transfer. Quantitative time
course and dose–response data were obtained for both wild-type
and mutant cells possessing an altered pheromone response. These
results paint a quantitative portrait of how regulators such as Sst2p
and the C-terminal tail of -factor receptor modulate the kinetics
and sensitivity of G protein signaling. We have explored critical
features of the dynamics including the rapid rise and subsequent
decline of active G proteins during the early response, and the
relationship between the G protein activation dose–response curve
and the downstream dose–response curves for cell-cycle arrest and
transcriptional induction. Fitting the data to a mathematical model
produced estimates of the in vivo rates of heterotrimeric G protein
activation and deactivation in yeast.
L iving organisms detect and respond to a variety of environ-mental cues through heterotrimeric G protein signal trans-
duction pathways. Genetic or pharmacologic perturbation of
these systems in humans can have significant medical conse-
quences (1). Many pharmaceutical agents are directed against
components of the G protein activationdeactivation cycle (1).
Achieving a quantitative understanding of this cycle and of the
relationship between G protein activation and downstream
physiology can aid in drug development.
One of the best studied heterotrimeric G protein signaling
systems is the yeast mating response in Saccharomyces cerevisiae
(2, 3). Haploid yeast cells respond to a peptide pheromone from
their partner by undergoing a series of events (e.g., cell-cycle
arrest, synthesis of new proteins) in preparation for mating. In a
cells, the pheromone -factor, secreted by  cells, activates the
G protein coupled -factor receptor (Ste2p). Most of the
components of this pathway have been identified, including the
receptors Ste2p and Ste3p (a-factor receptor), the G protein
subunits Gpa1p (G), Ste4p (G), and Ste18p (G), and the G
protein regulator (RGS) Sst2p.
Yeast geneticists have isolated mutants possessing altered
sensitivity to the pheromone -factor (4). In particular, the
following all confer an -factor supersensitive phenotype: the
deletion of BAR1 (bar1), which encodes a secreted protease
that degrades -factor, the deletion of SST2 (sst2), and the
removal of the C-terminal tail of -factor receptor STE2
(ste2300). It is important to provide a quantitative description of
how these mutations affect the G protein cycle to complement
the existing qualitative understanding.
Until recently, the dynamics of heterotrimeric G protein
activation have been primarily studied through in vitro systems
(5), or through indirect in vivo readouts such as changes in cell
membrane electrochemical properties (6). Devreotes and col-
leagues (7) used fluorescence resonance energy transfer (FRET)
between the -subunit and the -subunits to measure directly
in vivo G protein activation in Dictyostelium discoideum cells.
Inactive heterotrimer produced a specific FRET signal, and the
addition of the stimulating ligand adenosine 3,5-cyclic mono-
phosphate (cAMP) led to a dose-dependent loss of FRET.
In this article, we performed a quantitative investigation of the
in vivo dynamics and regulation of G protein activation in both
wild-type yeast haploid a cells and mutant cells containing
-factor supersensitivity mutations. We constructed strains pos-
sessing genomic copies of the FRET pairs CFP-GPA1 (G) and
STE18-YFP (G), which replaced their cognate genes. We
observed the dose-dependent loss of FRET on -factor addition,
which was quantitated by fluorometer. The kinetics and dose
response of G protein activation were measured and compared
with the pheromone responsiveness of two downstream events,
cell-cycle arrest, and transcriptional activation of pheromone-
inducible genes. Finally, we fit the data to a mathematical model
that furnishes a detailed description of the yeast heterotrimeric
G protein cycle (Fig. 1) and also enables quantitative explana-
tions of the data.
Materials and Methods
Plasmids and Strains. All yeast strains used were isogenic deriv-
atives of W303. Genetic techniques were performed according to
standard methods (8). Details on strain construction are pre-
sented in Supporting Text and Table 2, which are published as
supporting information on the PNAS web site, www.pnas.org.
FRET Measurements. Exponentially growing cells were treated
with -factor for a specified period, then4 OD600 units of cells
were removed from the YPAD medium [yeast extractpeptone
dextrose (YPD) medium supplemented with adenine] and either
(i) chilled, spun down, washed once with PBS, and resuspended
in 100 l of PBS, or (ii) fixed with ice-cold formaldehyde-PBS
solution (3.7% formaldehyde in PBS) for 8 min, washed once
with PBS, then resuspended in 100 l of PBS. Formaldehyde
fixation did not have a significant effect on the FRET signal; the
spectra for FRET strain TMY101 were similar under the two
preparation conditions. The cells were then placed into a 96-well
plate and were read by using a Gemini XS SpectraMAX
fluorometer. Quantification was performed on single wave-
length readings with excitation at 434 nm and emissions moni-
tored at 475 and 530 nm. For the representative spectra data
presented in Fig. 2, the excitation was at 430 nm and the
emissions were scanned from 466 to 600 nm.
Time Course and Dose–Response FRET Experiments. In the time
course experiments, 1 M -factor was added to cells in YPAD
Abbreviations: CFP, cyan fluorescent protein; YFP, yellow fluorescent protein; RGS, G
protein regulator; FRET, fluorescence resonance energy transfer.
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medium (30°C) at t  0. At different time points, the cells were
quenched by placing in the ice-cold formaldehyde-PBS solution,
and single-wavelength fluorescence measurements were made at
475 and 530 nm.
In the dose–response experiments, a single time point was
picked near the peak of the time course response for the relevant
range of -factor concentrations. This time point was 1 min for
TMY101, 3 min for TMY111, 2 min for TMY112, and 1 min for
TMY113. Different doses of -factor were added to separate
cultures, and the cells were then quenched in the formaldehyde-
PBS solution after the specified time.
Pheromone Response Assays. A pheromone-responsive reporter
gene (PFUS1-GFP) was constructed by using the promoter from
the FUS1 gene fused to GFP on the single-copy pRS316 plasmid.
This plasmid was transformed into the various strains. The cells
in YPAD medium were treated with the different doses of
-factor for 2 h. Approximately 1 OD600 unit of cells was
harvested, resuspended in 100 l of PBS, placed into a 96-well
plate, and read by using the Gemini fluorometer with the
excitation at 470 nm and emission at 510 nm.
Cell-cycle arrest was quantitated by treating exponentially
growing cells with different doses of -factor for 4 h and then
measuring the cell density (OD600) in a spectrophotometer.
Calculations to Determine Free G from FRET Data. The FRET
efficiency, Ei, was calculated from the raw 475530 ratio, ri, by
using the following formula:
Ei  E0
Emax  E0
  ri  r0rmax  r01 rmax1 ri .
For TMY101, E0  0.3 was the FRET efficiency and r0  0.52
was the 475530 ratio in the absence of -factor. Emax 0.18 was
the FRET efficiency and rmax  0.59 was the 475530 ratio 30 s
after the addition of 1 M -factor (see Supporting Text). Then,
we used the following simple linear relationship to determine the
fraction of free G:
[Gbg]i
Gt
 1
Ei
E0
.
Model Structure and Parameter Estimation. The model represents
the reactions depicted in Fig. 1 and was used to estimate the rates
of G protein activation and deactivation. The units of concen-
tration for the proteins are numbers of molecules per cell; the
concentration of the ligand -factor is in moles. The model is
comprised of four ordinary differential equations (ODEs) de-
scribing the dynamics of the four state variables: free receptor
(R), receptor bound to ligand (RL), inactive heterotrimeric G
protein (G), and active G-GTP (Ga). The output is the level of
free G ([Gbg]  Gt  [G]) and the input is the concentration
of -factor (L). The level of G-GDP (Gd) is determined by the
conservation relationship [Gd]  Gt  [G]  [Ga]. The ODEs
of the model are as follows: (i) d[R]dt  kRL [L][R]  kRLm
[RL]  kRd0 [R]  kRs; (ii) d[RL]dt  kRL [L][R]  kRLm
[RL]  kRd1[RL]; (iii) d[G]dt  kGa [RL][G]  kG1
[Gd][Gbg]; and (iv) d[Ga]dt  kGa [RL][G]  kGd [Ga]. Note
that the rate constant for G protein deactivation kGd  kGd1 for
SST2 strains and kGd  kGd0 for the sst2 strain.
The model contains 10 parameters. We determined the values
of seven of the parameters from direct experimental measure-
ments and information in the literature. These include the rates
of ligand-receptor association (kRL  2106 M1s1) and disso-
ciation (kRLm  1102 s1), receptor synthesis (kRs  4 mole-
cules per cell s1) and degradation (kRd0  4104 s1) with a
faster rate for ligand-bound receptor (kRd1  4103 s1) that
represents in aggregate the ligand-stimulated receptor down-
regulation reactions, and G protein heterotrimerization (kG1 
1 (molecule per cell)1 s1). We estimated the total number of
G proteins per cell (Gt) to be10,000 per cell from quantitative
Western blots and fluorescence quantification.
The rates of G protein activation [kGa 1105 (molecules per
cell)1 s1], Sst2p catalyzed G protein deactivation (kGd1  0.11
s1), and uncatalyzed G protein deactivation (kGd0  0.004 s1)
were identified from the FRET time course and dose–response
data. We selected the least-squares criterion as the error norm.
An optimization procedure, the simplex algorithm, was used to
find the parameter values that minimized the square error
between the model simulations and the data. We did not attempt
to characterize the distribution of our parameter estimates.
Results
Monitoring G Protein Activation by FRET. Janetopoulos et al. (7)
demonstrated that inserting cyan fluorescent protein (CFP) into
G1 from D. discoideum, and attaching yellow fluorescent
protein (YFP) to G, produced FRET when the G1 was
Fig. 1. Reaction diagram of heterotrimeric G protein cycle. The individual
reactions comprising the key dynamics of heterotrimeric G proteins in yeast
are represented along with the rate constants. The solid dot on the reaction
arrow indicates that the reaction is catalyzed by the protein connected to the
dot. The yellow circle attached to G represents YFP fused to Ste18p (G) and
the blue circle attached to G represents CFP fused to Gpa1p (G).
Fig. 2. G protein activation results in a loss of FRET. Shown is a representative
fluorescence spectra of TMY101 showing FRET. Cells were excited at 430 nm,
and the emission was detected by scanning from 466 to 600 nm. The control
(dashed-dot line) was the combined signal from TMY102 (CFP-Gpa1p) and
TMY103 (Ste18p-YFP). FRET was detected in TMY101 (solid line) as a decrease
in the CFP emission signal (475 nm) and an increase in the YFP emission spectra
(530 nm) relative to the control. Treating the TMY101 cells with -factor for 1
min resulted in a loss of FRET (dashed line).
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bound to G in the inactive heterotrimeric state. Examining the
crystal structures of heterotrimeric G proteins (9), we observed
that the N terminus of G is in close proximity to the C terminus
of G. We positioned CFP directly after the N-terminal myris-
toylation site (10) of G (CFP-Gpa1p) and we inserted YFP just
in front of the prenylation consensus sequence (11) near the C
terminus of G (Ste18p-YFP). Both proteins were functional as
demonstrated by their ability to complement their respective
deletion strains.
To ensure that each cell contained a single copy of both FRET
constructs under the appropriate transcriptional regulation, we
replaced the genomic copies of GPA1 and STE18 with CFP-
GPA1 and STE18-YFP, respectively, in a haploid a cell back-
ground containing the bar1 mutation (TMY101). Western
blots demonstrated that the steady-state concentrations of the
fluorescent fusion proteins were comparable to the levels of the
wild-type proteins (data not shown). The pheromone response
was also not altered significantly as measured by cell-cycle arrest
(halo assay), and by the induction of PFUS1-GFP.
The reporter strain TMY101 exhibited a strong FRET signal
in the absence of -factor when measured using a fluorometer.
Excitation of CFP in TMY101 resulted in a stronger YFP
emission signal and weaker CFP signal compared with the
combined spectra from the CFP-GPA1 strain (TMY102) and the
STE18-YFP strain (TMY103), indicating the presence of FRET
(Fig. 2). We estimated the FRET efficiency to be 30%.
The addition of -factor resulted in a loss of the FRET signal
in a dose-dependent fashion that required the presence of
functional -factor receptor. Removal of -factor led to the
recovery of the FRET signal (data not shown). These data argue
against the nonspecific dimerization between CFP and YFP
being responsible for the FRET signal.
We attributed the -factor-induced loss of FRET to G protein
activation that resulted in the dissociation of CFP-Gpa1p from
Ste18p-YFP. We quantified the level of active G proteins by
using the ratio of the emission signal at 475 nm (CFP) to the
emission signal at 530 nm (YFP) after excitation at 434 nm.
Increased G protein activation increased this ratio. Confocal
imaging showed that the loss of FRET occurred primarily on the
cell surface (data not shown).
In Vivo Kinetics of G Protein Activation. Time course experiments
were performed to follow the in vivo kinetics of the formation of
active G proteins. On addition of saturating concentrations of
-factor (1 M), there was near maximal G protein activation at
the first time point of 10 s (Fig. 3A). Levels of active G proteins
peaked at 30 s, and the levels then underwent a decline that
bottomed out at the 7.5-min time point. The 475530 ratios in
Fig. 3 were normalized by first subtracting the baseline ratio at
t  0, r0, to obtain the baseline adjusted ratio (ri  r0) and then
dividing by the adjusted ratio at its maximum (rmax  r0), when
t  30 s, to obtain the normalized ratio (ri  r0)(rmax  r0).
Interestingly, when monitored over a period of one hour, the
475530 ratio continued to rise after 7.5 min (Fig. 3A Inset). We
suspected that this increase reflected the polarized, pheromone-
induced synthesis of receptor, G, and G. To test this
hypothesis, the protein synthesis inhibitor cycloheximide was
added along with -factor at t  0. The cycloheximide-treated
cells exhibited the rapid activation and deactivation phases, but
no recovery of the 475530 ratio after the decline; instead the
normalized ratio stayed close to zero (Fig. 3A). As further
evidence, the kinetics of the -factor stimulated synthesis of
Gpa1p were measured by using a GFP-GPA1 strain. The time
course of the increase in levels of GFP-Gpa1p paralleled the rise
in the 475530 ratio (data not shown).
Our hypothesis was that the decline in active G proteins was
caused at least in part by ligand-stimulated receptor endocytosis.
Receptor internalization is important for adaptation in many G
protein systems (12). The decay in the 475530 ratio for the
cycloheximide-treated cells was fitted to an exponential with a
half-time of 3 min (Fig. 3A, red dashed line). This value is in
rough agreement with, but slightly faster than, the rate of
receptor endocytosis (t0.5  4.5 min) measured by labeled
-factor internalization (13). To further investigate this issue, the
wild-type -factor receptor was replaced with a mutant version
lacking the C-terminal tail beyond residue 300 so that ligand-
stimulated endocytosis was severely impaired (14). G protein
activation was not detrimentally affected, but G protein deac-
tivation was dramatically curtailed in the mutant (Fig. 3B). The
truncated receptor protein possesses other abnormalities, such
as not being hyperphosphorylated (15), which are likely to
contribute to this effect along with the endocytosis defect.
The time course of G protein activation was also monitored in
an sst2 strain (TMY111), which was expected to exhibit slower
G protein deactivation. Indeed, the decrease in the 475530
signal was considerably more modest than for the SST2 strain.
Fig. 3. Kinetics of G protein activation. (A) Time course of G protein activation. TMY101 cells were treated with 1 M -factor, and the FRET emission ratio
475530 was measured at different time points from 0 to 10 min (black). These values were normalized by subtracting the baseline ratio at t0, and then dividing
by the peak baseline adjusted ratio at t 30 s. In a second experiment, the protein synthesis inhibitor cycloheximide was added with -factor at the start (red).
The time course of G protein activation at later times up to 60 min is also shown (Inset). The SE from three independent measurements are represented. (B) Time
course of G protein activation in sst2 and ste2300 cells. TMY111 (sst2, blue) and TMY112 (ste2300, red) cells were treated with 1M-factor, the FRET 475530
ratio was measured from 0 to 10 min, and the baseline was adjusted and then normalized to the ratio at the 30-s time point. The data from TMY101 are redrawn
in black for comparison.
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Because receptor endocytosis was not affected in the sst2 strain
(data not shown), we concluded that in the absence of Sst2p, the
rate of G protein deactivation was sufficiently slow to be rate
limiting for the reassociation of the heterotrimer. Thus, the
kinetics of G protein activation were rather complex: the initial
fast rise was followed by a fall that required both Sst2p and the
C-terminal tail of Ste2p, and the subsequent long-term increase
in the 475530 signal depended on new protein synthesis.
Dose–Response Curves to -Factor in Wild-Type and Mutant Cells.
Understanding and manipulating dose–response curves are key
challenges in pharmacology. To what extent do the kinetics of
ligand-binding and the dynamics of G protein activation
deactivation determine the dose response of events further down
the signaling pathway? The typical measured outputs for the
yeast pheromone response are cell-cycle arrest and transcrip-
tional activation; there are many intervening reactions including
the mitogen-activated protein (MAP) kinase cascade between
these processes and the G protein cycle, which could modulate
the sensitivity of the response.
The dose response to -factor was measured at four different
stages in this signaling pathway: (i) receptor binding (ligand-
binding assay); (ii) G protein activation (loss of FRET); (iii) tran-
scriptional induction (PFUS1-GFP reporter gene); and (iv) cell-
cycle arrest (cell density). The dose–response curves were
normalized by dividing by the response to saturating levels of
-factor (1 M). Ligand-binding and G protein activation rep-
resent the early responses to pheromone (within a few minutes).
We assayed transcriptional activation 2 h after treatment and
cell-cycle arrest 4 h after pheromone addition.
We also investigated the effect on these dose–response curves
of three mutations possessing an -factor supersensitive pheno-
type: (i) sst2; (ii) ste2300 (deletion of the C-terminal tail beyond
residue 300); and (iii) bar1. It is thought that these mutations
mainly exert their effect by perturbing the G protein activation
deactivation cycle by means of one of the three principal
mechanisms for down-regulating G protein signaling: (i) G
protein deactivation; (ii) receptor desensitization; and (iii) re-
moval of the ligand -factor.
TMY101 cells (STE2 SST2 bar1) were treated with a
range of -factor concentrations from 0.1 nM to 1 M. We
measured the loss of FRET after 1 min, which was close to the
peak response for the different doses. Interestingly, the four
dose–response curves for receptor affinity, G protein activation,
transcriptional induction, and cell-cycle arrest overlapped quite
closely at 5 nM (Fig. 4A). One explanation is that receptor
affinity is the key determinant of the dose–response behavior for
this system.
Results from the sst2 cells (TMY111) ruled out this hypoth-
esis; in these cells, the receptor affinity was unchanged at 5 nM,
whereas the other three curves were shifted to the left 20-fold
to0.3 nM (Fig. 4B). These data reflect the increased sensitivity
to -factor resulting from a slower rate of G protein deactivation
caused by the absence of Sst2p. Thus, perturbing the dynamics
of G protein activationdeactivation was sufficient to modulate
the downstream dose response, independent of any changes in
receptor affinity. Furthermore, these data provide support for
the view that the G protein cycle is the primary site of action for
Sst2p, a large protein containing multiple domains, during the
early stages of the pheromone response.
The ste2300 cells (TMY112) also displayed increased sensi-
tivity to -factor as demonstrated by the shift to the left of the
G protein activation, transcriptional induction, and cell-cycle
arrest dose–response curves to a K0.5 of 0.6 nM (Table 1). The
measured Kd for -factor binding to truncated receptor was
elevated to 15 nM, representing a decrease in receptor affinity.
Because tail-less Ste2p is endocytosed at a slower rate (14), the
steady-state numbers of receptors on the cell surface were
increased from10,000 molecules per cell to60,000 molecules
per cell. Raising the number of surface receptors may partially
explain the more sensitive response. Thus, removal of the
C-terminal tail of -factor receptor had a direct effect on the G
protein cycle, and once again the downstream processes were
closely attuned to these changes in active G protein levels.
Fig. 4. Overlap of different dose–response curves in G protein signaling. (A) Pheromone dose–response behavior for TMY101 cells. -Factor was added at
different doses from 0.1 nM to 1 M. Four different pheromone dose–response readouts were measured: (i) receptor affinity (black triangles), (ii) G protein
activation (red circles), (iii) transcriptional induction of PFUS1-GFP (green squares), and (iv) cell-cycle arrest (blue diamonds). The data points from each readout
were normalized to the response at 1M and were then fit with a Hill curve. (B) Pheromone dose–response behavior of TMY111 (sst2) cells. -Factor was added
at different doses from 0.03 nM to 1 M. The data from the four different dose–response readouts are presented as described above.
Table 1. Summary of pheromone dose–response behavior
Strain
K0.5, nM
FRET
Transcriptional
activation
Cell-cycle
arrest
Receptor
binding
TMY101 4  1 5  0.3 6  1 6  3
sst2 0.3  0.03 0.3  0.03 0.2  0.02 5  1
ste2300 0.7  0.1 0.6  0.1 0.3  0.03 15  3
BAR1 7  1 1000  300 1500  200 ND
The K0.5 values are shown from the dose–response curves of four strains for
four outputs: G protein activation (FRET), transcriptional activation, cell-cycle
arrest, and ligand binding to receptor. Also displayed are the SE for at least
three independent measurements. ND, not determined.
Yi et al. PNAS  September 16, 2003  vol. 100  no. 19  10767
CE
LL
BI
O
LO
G
Y
All of the above strains were bar1 so that -factor would not
be degraded after administering the dose. Testing a BAR1
strain (TMY113), we found that early G protein activation was
relatively unchanged from the bar1 TMY101 cells, whereas the
later responses were 100-fold less sensitive (Table 1). We
reasoned that this difference arose because it takes time for the
protease Bar1p to remove the -factor. Indeed, the 475530 ratio
for BAR1 cells treated with 100 nM -factor steadily decreased
over a period of 30 min to near its baseline pretreatment value
(data not shown).
Rate Constants for G Protein Activation and Deactivation. The rates
of G protein activation and deactivation were estimated by fitting
the time course and dose–response data to a model of the
heterotrimeric G protein cycle describing the reactions in Fig. 1.
The complexity of the model was minimized so that it did not
dwarf the available data, while capturing the essential dynamics
of this process. The model consisted of four ordinary differential
equations and 10 parameters, 7 of which were specified based on
our own direct measurements as well as data reported in the
literature (see Materials and Methods). The remaining three
parameters, the rate of G protein activation (kGa), and the
Sst2p-catalyzed (kGd1) and uncatalyzed (kGd0) rates of G protein
deactivation, were estimated from the FRET data.
Changes in FRET efficiency provided a direct measure of the
fraction of G proteins that were associated as inactive hetero-
trimers. We converted the raw 475530 emission ratios into
FRET efficiencies (see Materials and Methods), thus processing
the data into a form suitable for fitting the model. As it turned
out, the 475530 ratio was roughly proportional to the level of
free G.
Optimization techniques were applied to identify the param-
eter values for kGa and kGd that minimized the least-square error
between the model simulations and the data. By using the FRET
time course and dose–response data for TMY101, we obtained
estimates of kGa  1105 (molecules per cell)1 s1 and kGd1 
0.1 s1 for the catalyzed rate of G protein deactivation when
Sst2p is present at wild-type levels. The fitted model reproduced
the fast rise, subsequent decline, and peak amplitude of G
protein activation (Fig. 5A), as well as the K0.5 of the dose–
response data (Fig. 5B). The model captured the general trends
of the data, but not the finer features, which presumably would
require a more detailed model.
To estimate the uncatalyzed rate of G protein deactivation, we
assumed that all of the parameter values were the same in the
sst2 strain TMY111 as in TMY101, with the exception of kGd
kGd0, which was fitted to the time course and dose–response data
of TMY111. The best estimate of kGd0 was 0.004 s1. As an
independent check, we measured the decay constant of the
decline in G protein activation in TMY111 treated with cyclo-
heximide to be0.002 s1 (data not shown). From the estimates
of kGd0 and kGd1, we calculated that the stimulation of G protein
deactivation by Sst2p was 25-fold, which is consistent with in
vitro data in which Sst2p produced an ‘‘at least 20-fold’’ increase
in GTP hydrolysis by Gpa1p (16). RGS proteins typically accel-
erate the GTPase activity of G by 10- to 1000-fold (17, 18).
Discussion
FRET was used to monitor the association state of the G protein
heterotrimer. There were multiple pieces of evidence supporting
the quantitative correlation between the decrease in the FRET
signal, measured as the 475530 ratio, and the levels of active G
proteins: (i) the increase in the 475530 ratio was dose-
dependent on -factor; (ii) the time course of the 475530 ratio
was consistent with existing indirect data on the kinetics of G
protein activation and deactivation; (iii) mutations expected to
perturb the G protein cycle had pronounced effects on the
kinetics and dose response of the 475530 ratio; and (iv) the dose
response of the 475530 ratio closely matched the dose response
of two downstream readouts in both wild-type and mutant
strains.
The dynamics of the activated G proteins were complex. After
treatment with saturating concentrations of -factor, there was
an initial fast rise in the 475530 ratio, followed by a decline,
which we attributed to receptor endocytosis and other regulatory
processes that depend on the C-terminal tail of Ste2p, and then
a more gradual recovery that required new protein synthesis. In
contrast, in Dictyostelium there was a fast rise in G protein
activation, which reached a plateau without any decline over a
period of 18 min (7). Consistent with this species difference is the
observation that cAMP receptor continues to activate G pro-
teins, even after phosphorylation (7).
Dose–Response Behavior and Pharmaceutical Implications. The yeast
pheromone response system stretches from the G protein cycle
at the start to downstream processes such as cell polarization and
cell-cycle arrest. There are several pieces of evidence that argue
that much of the control of this system occurs at the front end
in the G protein cycle. First, mutations with the most dramatic
pheromone supersensitiveresistant phenotypes affect genes
involved in the G protein dynamics (4, 15, 19–21). Here, we
demonstrated quantitatively that three of these mutations (sst2,
ste2300, and bar1) did indeed affect G protein activation
deactivation in a direct and substantial manner. Second, we have
Fig. 5. Fitting the mathematical model to the TMY101 data. (A) Experimental data and model simulations describing the time course of G protein activation
in TMY101. Two of the model parameters (kGa and kGd1) were fit to the data. The normalized 475530 data were processed into the fraction of total G proteins
that are active (F). A simulation of the fitted model in response to an input of 1 M -factor is presented (black line). (B) Experiments and modeling describing
the G protein activation dose–response behavior of TMY101. The data (F) and simulations (black line) were normalized to the output value at 1 M -factor.
A time point of t  60 s was used. The error bars represent the SE from three independent measurements.
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shown that perturbations in the sensitivity of the G protein cycle
were transmitted to the downstream processes without any
attenuation. Finally, many of the mating partner discrimination
mutations that reduced the ability of a cells to distinguish the 
cell producing the highest level of pheromone, were found in
genes encoding for components of the heterotrimeric G protein
cycle (22).
An interesting finding was the substantial overlap of the
various dose–response curves. The K0.5 values for G protein
activation, transcriptional induction, and cell-cycle arrest were
approximately the same for each strain. One consequence is that
there is greater coordination between upstream and downstream
processes in terms of responding to the same critical range of
ligand concentration. In mammalian G protein systems, the good
correlation between the Kd for receptor-antagonist binding and
the IC50 values for inhibiting the corresponding physiologically
significant downstream process suggests that upstream and
downstream dose–response curves are aligned as in yeast (23).
Many therapeutic agents are directed against G protein-
coupled receptors or against proteins that modulate the levels of
the ligand, such as transporters. This work presents quantitative
evidence that the overall G protein cycle dynamics determines
the dose response of G protein systems, not just the receptor-
ligand dynamics. Thus, both RGS proteins and proteins that
down-regulate receptor activity (e.g., G protein receptor ki-
nases) should prove to be equally effective targets for future
generations of drugs.
Evaluating the Rate Constants for G Protein Activation and Deacti-
vation. We estimated the in vivo rates of G protein activation and
deactivation by fitting a model of the G protein dynamics to the
FRET time course and dose–response data. There have been no
in vitro measurements of receptor-catalyzed G protein activation
in yeast. Although Dohlman and colleagues (16) have measured
the in vitro rates of both Sst2p-catalyzed and uncatalyzed GTP
hydrolysis by yeast G, Gpa1p, it is difficult to make a direct
comparison to the in vivo data (30°C), because the in vitro
experiments were performed at 4°C.
A 25-fold enhancement of G protein deactivation in the
presence of SST2 was observed. This finding is consistent with
the approximate 20-fold stimulation of Gpa1p GTPase activity
by Sst2p measured in vitro (16). It is important to note that this
degree of enhancement occurred at wild-type levels of Sst2p.
Data in the literature indicate that overexpressing Sst2p further
accelerates G protein deactivation (19), suggesting that the rate
of G protein deactivation depends on the concentration of Sst2p.
The visual phototransduction cascade is the most quantita-
tively characterized G protein signaling system (24). The initial
rate of G protein activation was estimated to be100 G proteins
per second per activated rhodopsin (25), which is 1,000-fold
faster than the yeast rate, which is 0.1 G proteins per second per
activated receptor. Likewise, the rates of G protein deactivation
were 10-fold faster than the corresponding yeast values: the
GTPase activity of transducin was 1 s1 in the presence of RGS9
and 0.02 s1 in the absence of RGS9 (26). Future experiments
are needed to determine whether the slow G protein activation
kinetics in yeast are the consequence of intrinsically inefficient
receptor or regulatory mechanisms designed to restrain the
activation rate.
Linderman and colleagues (27) have proposed a mathematical
model of G protein dynamics in human neutrophils in response
to N-formyl peptide. The simple structure of our model is similar
to their model. Interestingly, many of the estimates of the kinetic
constants for the neutrophil system were not too different from
the yeast values, including a G protein deactivation rate of 0.2 s1
(kGd1  0.1 s1) and a ligand-stimulated receptor internaliza-
tion rate of 3.3103 s1 (kRd1  4103 s1).
Finally, a priority for the future is to investigate the feedback
regulation of the heterotrimeric G protein cycle, especially
mechanisms acting through Sst2p and modification of the re-
ceptor tail. Feedback control is necessary to ensure the robust-
ness of the response in the presence of disturbances.
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